摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1,5-Dimethyl-1H-indazol-3-ylamine | 1260827-67-5

中文名称
——
中文别名
——
英文名称
1,5-Dimethyl-1H-indazol-3-ylamine
英文别名
1,5-Dimethylindazol-3-amine
1,5-Dimethyl-1H-indazol-3-ylamine化学式
CAS
1260827-67-5
化学式
C9H11N3
mdl
——
分子量
161.206
InChiKey
YIQNNSJRVFRARU-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    335.4±22.0 °C(Predicted)
  • 密度:
    1.23±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.6
  • 重原子数:
    12
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.22
  • 拓扑面积:
    43.8
  • 氢给体数:
    1
  • 氢受体数:
    2

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    1,5-Dimethyl-1H-indazol-3-ylamine亚硝酸特丁酯 作用下, 以 四氢呋喃 为溶剂, 反应 1.0h, 以82%的产率得到1,5-dimethyl-1H-indazole
    参考文献:
    名称:
    A method for the regioselective synthesis of 1-alkyl-1H-indazoles
    摘要:
    A method for the regioselective synthesis of 3-unsubstituted 1-alkyl-1H-indazoles, starting with 2-halobenzonitriles and N-alkylhydrazines, is described. The two-step reaction pathway proceeds through the intermediacy of 1-alkyl-3-amino-1H-indazoles followed by reductive deamination. (C) 2013 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.tet.2013.03.042
  • 作为产物:
    描述:
    2-氟-5-甲基苯腈甲基肼乙醇 为溶剂, 以90%的产率得到1,5-Dimethyl-1H-indazol-3-ylamine
    参考文献:
    名称:
    A method for the regioselective synthesis of 1-alkyl-1H-indazoles
    摘要:
    A method for the regioselective synthesis of 3-unsubstituted 1-alkyl-1H-indazoles, starting with 2-halobenzonitriles and N-alkylhydrazines, is described. The two-step reaction pathway proceeds through the intermediacy of 1-alkyl-3-amino-1H-indazoles followed by reductive deamination. (C) 2013 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.tet.2013.03.042
点击查看最新优质反应信息

文献信息

  • 8-Substituted isoquinoline derivative and the use thereof
    申请人:Kaneko Shunsuke
    公开号:US20100261701A1
    公开(公告)日:2010-10-14
    The present invention relates to a compound represented by the following formula (1): wherein D 1 , A 1 , D 2 , R 1 , D 3 , and R 2 each have the same meaning as defined in the present specification or a salt thereof. The compound represented by the formula (1) or a salt thereof has an IKKβ inhibiting activity and the like and is useful for the prevention and/or treatment of IKKβ-associated diseases or symptoms and the like.
    本发明涉及一种由以下式(1)表示的化合物: 其中D1,A1,D2,R1,D3和R2分别具有与本说明书中定义的相同含义或其盐。由式(1)表示的化合物或其盐具有IKKβ抑制活性等,对于预防和/或治疗IKKβ相关疾病或症状等方面是有用的。
  • THERAPEUTIC COMPOUNDS
    申请人:Gilead Sciences, Inc.
    公开号:US20130281433A1
    公开(公告)日:2013-10-24
    Compounds disclosed herein including compounds of formula I′: and salts thereof are provided. Pharmaceutical compositions comprising compounds disclosed herein, processes for preparing compounds disclosed herein, intermediates useful for preparing compounds disclosed herein and therapeutic methods for treating an HIV infection using compounds disclosed herein are also provided.
    本文披露的化合物包括公式I′的化合物及其盐。还提供了包含本文披露的化合物的药物组合物、制备本文披露的化合物的方法、用于制备本文披露的化合物的中间体以及使用本文披露的化合物治疗HIV感染的治疗方法。
  • 8-SUBSTITUTED ISOQUINOLINE DERIVATIVE AND USE THEREOF
    申请人:Asahi Kasei Pharma Corporation
    公开号:EP2366699A1
    公开(公告)日:2011-09-21
    The present invention relates to a compound represented by the following formula (1): wherein D1, A1, D2, R1, D3, and R2 each have the same meaning as defined in the present specification or a salt thereof. The compound represented by the formula (1) or a salt thereof has an IKKβ inhibiting activity and the like and is useful for the prevention and/or treatment of IKKβ-associated diseases or symptoms and the like.
    本发明涉及下式(1)所代表的化合物: 其中 D1、A1、D2、R1、D3 和 R2 各具有与本说明书中定义相同的含义或其盐。式(1)代表的化合物或其盐具有 IKKβ 抑制活性等,可用于预防和/或治疗 IKKβ 相关疾病或症状等。
  • BENZOTHIAZOL-6-YL ACETIC ACID DERIVATIVES AND THEIR USE FOR TREATING AN HIV INFECTION
    申请人:Gilead Sciences, Inc.
    公开号:EP3070081B1
    公开(公告)日:2018-02-28
  • US8299055B2
    申请人:——
    公开号:US8299055B2
    公开(公告)日:2012-10-30
查看更多